Rheumatic Myocarditis Treatment Market Size

  • Report ID: 3325
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Rheumatic Myocarditis Treatment Market Size

Rheumatic Myocarditis Treatment Market size was over USD 1.1 billion in 2024 and is projected to reach USD 2.05 billion by 2037, growing at around 4.9% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of rheumatic myocarditis treatment is assessed at USD 1.19 billion.
 

The major factor attributed to market growth is the rising incidence of rheumatic heart disease among the global population and the increasing prevalence of rheumatic fever which is generating the need for rheumatic myocarditis treatment during the forecast period. According to a recently published report in 2021, it is estimated that around 34 million people around the world have rheumatic heart disease. Moreover, it is being calculated that 300,000 to 500,000 new cases of rheumatic fever are diagnosed every year worldwide.

In addition to the aforementioned factors, the rapid advancement in drugs and biotechnology is estimated to bring in lucrative growth opportunities for the expansion of the global rheumatic myocarditis treatment. Apart from this, the escalation in cases of rheumatic fever, and strep throat along with the growing prevalence of inflammatory diseases around the world is anticipated to create a positive outlook for market growth during the forecast period. Furthermore, another factor that is estimated to drive the rising focus of the governments of different nations to enhance healthcare facilities and medical offerings. Also, the rising cases of chronic diseases and cardiovascular disorders which lead to rheumatic myocarditis are forecasted to generate a high demand for rheumatic myocarditis treatment which is estimated to subsequently increase the market size in the upcoming years.


Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3325
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of rheumatic myocarditis treatment is assessed at USD 1.19 billion.

The rheumatic myocarditis treatment market size was over USD 1.1 billion in 2024 and is projected to reach USD 2.05 billion by 2037, growing at around 4.9% CAGR during the forecast period i.e., between 2025-2037. Rising prevalence of rheumatic fever and the growing availability of over-the-counter drugs will boost the market growth.

North America industry is likely to account for largest revenue share of 35% by 2037, propelled by increasing frequency of rheumatic fever and subsequently rheumatic myocarditis amongst several people, driven by rising awareness about the disease among people and high healthcare expenditure for treatment procedures.

The major players in the market are Siemens Healthcare GmbH, CryoLife Inc., Edwards Lifesciences Corporation, Neovasc Inc., HighLife SAS, Abbott Laboratories, Sanofi-aventis Groupe, Pfizer Inc., Boston Scientific Corporation, Medtronic PLC
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample